Asunto(s)
Anafilaxia/inducido químicamente , Anticuerpos Antiidiotipos/efectos adversos , Anticuerpos Monoclonales Humanizados/efectos adversos , Hipersensibilidad a las Drogas/etiología , Enfermedad del Suero/etiología , Anafilaxia/epidemiología , Canadá , Hipersensibilidad a las Drogas/epidemiología , Etiquetado de Medicamentos , Humanos , Omalizumab , Prevalencia , Vigilancia de Productos Comercializados , Enfermedad del Suero/epidemiología , Estados Unidos/epidemiologíaRESUMEN
Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose-responsive in vivo efficacy in our pre-clinical food intake model.
Asunto(s)
Fármacos Antiobesidad/síntesis química , Compuestos Aza/síntesis química , Agonistas del Receptor de Serotonina 5-HT2 , Agonistas de Receptores de Serotonina/síntesis química , Administración Oral , Animales , Fármacos Antiobesidad/química , Fármacos Antiobesidad/farmacología , Compuestos Aza/química , Compuestos Aza/farmacología , Perros , Diseño de Fármacos , Haplorrinos , Humanos , Obesidad/tratamiento farmacológico , Ratas , Receptor de Serotonina 5-HT2C/metabolismo , Agonistas de Receptores de Serotonina/química , Agonistas de Receptores de Serotonina/farmacologíaRESUMEN
Brain-penetrable proline amides were developed as 5HT2c agonists with more than 1000-fold binding selectivity against 5HT2b receptor. After medicinal chemistry optimization and SAR studies, orally active proline amides with robust efficacy in a rodent food intake inhibition model were uncovered.
Asunto(s)
Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/uso terapéutico , Obesidad/tratamiento farmacológico , Prolina/farmacocinética , Prolina/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT2 , Administración Oral , Amidas/farmacocinética , Amidas/farmacología , Amidas/uso terapéutico , Animales , Fármacos Antiobesidad/farmacología , Encéfalo/metabolismo , Perros , Ingestión de Alimentos/efectos de los fármacos , Humanos , Prolina/análogos & derivados , Prolina/farmacología , Ratas , Receptor de Serotonina 5-HT2C/metabolismo , Relación Estructura-ActividadRESUMEN
Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compound. Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.
Asunto(s)
Anabolizantes/química , Pirimidinonas/química , Receptores Sensibles al Calcio/antagonistas & inhibidores , Administración Oral , Anabolizantes/administración & dosificación , Anabolizantes/farmacocinética , Animales , Masculino , Hormona Paratiroidea/metabolismo , Pirimidinonas/administración & dosificación , Pirimidinonas/farmacocinética , Ratas , Ratas Sprague-Dawley , Receptores Sensibles al Calcio/metabolismo , Relación Estructura-ActividadAsunto(s)
Antiasmáticos/uso terapéutico , Anticuerpos Antiidiotipos/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Asma/terapia , Prednisona/efectos adversos , Insuficiencia Suprarrenal/etiología , Insuficiencia Suprarrenal/inmunología , Insuficiencia Suprarrenal/terapia , Asma/inmunología , Asma/fisiopatología , Dolor de Espalda/etiología , Dolor de Espalda/inmunología , Dolor de Espalda/terapia , Niño , Humanos , Masculino , Omalizumab , Prednisona/uso terapéutico , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Hereditary angioedema (HAE) is a rare autosomal dominant disease most commonly associated with defects in C1 esterase inhibitor (C1-INH). HAE manifests as recurrent episodes of edema in various body locations. Atypical symptoms, such as ascites, acute respiratory distress syndrome, and hypovolemic shock, have also been reported. Management of HAE conventionally involves the treatment of acute attacks, as well as short- and long-term prophylaxis. Since attacks can be triggered by several factors, including stress and physical trauma, prophylactic therapy is recommended for patients undergoing surgery. Human plasma-derived C1-INH (pdC1-INH) concentrate is indicated for the treatment of both acute HAE attacks and pre-procedure prevention of HAE episodes in patients undergoing medical, dental, or surgical procedures. We report the first case of a patient with HAE who experienced an abdominal attack precipitated by a retroperitoneal bleed while being converted from warfarin to heparin in preparation for surgery. Subsequently, the patient had a protracted course in hospital with other complications, which included hypovolemic shock, ascites, severe sepsis from nosocomial pneumonia, renal and respiratory failure. Despite intensive interventions, the patient remained in a critical state for months; however, after a trial of daily intravenous infusion of pdC1-INH concentrate (Berinert®, CSL Behring GmbH, Marburg, Germany), clinical status improved, particularly renal function. Therefore, pdC1-INH concentrate may be an effective treatment option to consider for critically-ill patients with HAE.
RESUMEN
BACKGROUND: Hereditary Angioedema (HAE) is a rare autosomal dominant condition characterized by episodic angioedema, which may be triggered by invasive procedures and surgery. C1 inhibitor (C1 INH) was approved in the United States and Canada in 2009 and 2010, respectively, for the treatment of acute attacks. Most recently in April 2013, it was approved in Europe for short-term prophylaxis (STP), prior to medical, dental, or surgical procedures, to prevent HAE attacks in both children and adults. Currently, C1 INH is not approved in Canada or the United States for STP of HAE attacks. Our objective was to demonstrate the effectiveness of C1 INH as a short-term prophylactic treatment for patients with Type I HAE undergoing invasive surgical procedures. METHODS: A retrospective chart review between 1997-2013 was performed at one Canadian Tertiary Care Allergy and Asthma Clinic affiliated with The Ottawa Hospital, in Ottawa, Canada. The standard dose of C1 INH for STP was 10 or 20 U/kg. RESULTS: In all 24 procedures, there were no post-procedure HAE attacks after short-term prophylactic administration of C1 INH. CONCLUSIONS: In this retrospective chart review at one tertiary care Allergy and Clinical Immunology Clinic, short-term prophylactic use of C1 INH was found to be effective at preventing post-procedure HAE attacks, in patients diagnosed with Type I HAE.